{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-052718","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.857070+00:00","generated_at":"2026-06-08T05:14:11.104516+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Roivant reports Q2 net loss $331M; announces $7.1B Telavant sale to Roche","bullets":["Net loss $331.1M ($0.40/share) vs $315.9M prior year; revenue $37.1M up from $12.5M.","Sold Telavant to Roche for $7.1B upfront + $150M milestone; Roivant net proceeds ~$5.2B.","VTAMA net product revenue $18.4M in quarter; over 250k prescriptions since launch.","Pro forma cash ~$7.0B after Telavant and Immunovant offerings; R&D spend $132M.","IMVT-1402 Phase 1 data show dose-dependent IgG reduction with no significant albumin/LDL-C changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-052718","json":"https://secwatch.observer/filing/0001140361-23-052718.json","markdown":"https://secwatch.observer/filing/0001140361-23-052718.md","text":"https://secwatch.observer/filing/0001140361-23-052718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/0001140361-23-052718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/ef20014462_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:14:11.104516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c328591d3d5feaff5cbae1acf517b38eafede4b","claim":"Roivant Sciences Ltd. reported financial results for the second quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/0001140361-23-052718-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}